Amendment to Clinical Trial Agreement between hVIVO Services Ltd and AIM ImmunoTech Inc.
This amendment updates the Clinical Trial Agreement between hVIVO Services Ltd and AIM ImmunoTech Inc. AIM will pay a final invoice of £46,936.86 to hVIVO, which settles all outstanding fees for services under the original agreement dated September 27, 2021. No further charges will be incurred by AIM for this study. If AIM decides to proceed with a new challenge study with quarantine scheduled before November 2022, a new agreement will be required and a quarantine cancellation fee of £317,152 will apply.
EXHIBIT 10.80
AMENDMENT
This will act as an amendment to the existing Clinical Trial Agreement dated 27 September 2021. hVIVO Services Ltd (HVIVO) will submit to AIM ImmunoTech Inc. (AIM), today, a final invoice in the amount of £46,936.86 based on the financial reconciliation dated 28 February 2022 and the payment by AIM of this invoice will constitute full and final payment for services and fees incurred in relation to the agreement of 27 September 2021 and no additional charges will be received or incurred by AIM from HVIVO in relation to this study.
If AIM elects to move forward with a challenge study and the quarantine is scheduled prior to November 2022, it is agreed, a new agreement will be entered into and the Quarantine Cancellation fee, £317,152 will be recovered.
IN WITNESS WHEREOF, the Parties have executed this Agreement to be effective as of the fully executed date below.
| hVIVO Services Ltd | AIM ImmunoTech Inc. | |
| /s/ Dori Kadmon | /s/ Peter W. Rodino | |
| Signature | Signature | |
| Dori Kadmon | Peter W. Rodino, III | |
| Name | Name | |
| Head of Legal | COO & General Counsel | |
| Title | Title | |
| 02 March 2022 | March 1, 2022 | |
| Date | Date |
